{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-096257","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.532204+00:00","generated_at":"2026-05-18T06:23:49.923127+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning","bullets":["Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.","Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.","FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.","Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.","Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-096257","json":"https://secwatch.observer/filing/0000950170-25-096257.json","markdown":"https://secwatch.observer/filing/0000950170-25-096257.md","text":"https://secwatch.observer/filing/0000950170-25-096257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-20250714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:23:49.923127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf2668fb35c15d522cbb5c8ec68489d7c334013d","claim":"Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).","evidence_excerpt":"on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between approximately $32 million and $37 million"},{"label":"Headcount","value":"approximately 36% of the Company's workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}